Pharmassist's R&D Department is focusing on the development and commercialization of novel molecular diagnostic products in the oncology field.
Our business strategy on the development of CE-IVD diagnostic products has started since 2014, acquiring our key assets through the building of our own patent portfolio and trademark/brand name. Until now, Pharmassist has acquired ten (10) granted patents under its name by PCT and national applications in the major market areas such as USA, Europe, Japan, China, Canada, Hong Kong and Israel:
- EP3198026
- US011279979B2
- CA2957396
- CN106715723
- IL250392
- JP6770957
- HK1241934
- ΙΝ417895
- EP3368683
- US12270081B2
Pharmassist makes use of new privately owned manufacturing facilities, operating in accordance with all relevant quality standards and has been certified according to ISO 9001, ISO 13485 requirements and Manufacturing License for IVD medical devices.
Our vision is to provide innovative, timely, and integrity actionable diagnostic information in every patient, enhancing the precision strategy for cancer treatment and improving the health outcome.
Join us on our mission to detect and monitor cancer through innovative in vitro solutions that empower both patients and healthcare providers to take proactive steps toward personalized treatment plans, ultimately maximizing patient outcomes. We believe in a future where every patient receives the most effective and timely care, and we are proud to be part of that journey.
